Bolt Biotherapeutics
Michael Alonso, Ph.D, vice president of immunology & pharmacology, is a scientific co-founder at Bolt Biotherapeutics and co-invented Bolt’s promising technology. Michael is passionate about translating scientific discoveries into therapies that ensure cancer patients become cancer survivors. Dr. Alonso has deep expertise with myeloid biology and has over 10 years of experience in immunology, neuroscience and transplant biology. Prior to joining Bolt, Michael served as the lead scientist at a Bay Area biotechnology start-up and has held leadership roles at Stanford University. Michael is a well-published scientist who earned his Ph.D. from Stanford University School of Medicine and his Certificate in Entrepreneurship from Stanford’s Graduate School of Business. Michael graduated with distinction from the University of Illinois at Urbana-Champaign where he obtained his bachelors of science in molecular and cellular biology.
This person is not in any offices
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.